Insider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells $43,466.80 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 169 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $257.20, for a total value of $43,466.80. Following the completion of the sale, the insider owned 99,645 shares of the company’s stock, valued at $25,628,694. The trade was a 0.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Down 0.5%

Shares of NASDAQ ONC opened at $262.68 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The firm has a market capitalization of $28.82 billion, a price-to-earnings ratio of 58.77 and a beta of 0.49. The stock has a 50 day moving average price of $296.83 and a 200 day moving average price of $312.94. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $239.25 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. Sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. EFG International AG purchased a new position in BeOne Medicines in the 4th quarter worth $25,000. Leonteq Securities AG purchased a new position in BeOne Medicines in the 4th quarter worth $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $35,000. CWM LLC raised its position in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in BeOne Medicines during the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on ONC shares. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. Royal Bank Of Canada increased their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research report on Tuesday, June 2nd. Wolfe Research initiated coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective for the company. Finally, Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.